DNA lesions correlate with lymphocyte function after selective internal radiotherapy.


Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 28 09 2018
accepted: 11 03 2019
pubmed: 17 3 2019
medline: 4 6 2019
entrez: 17 3 2019
Statut: ppublish

Résumé

In patients with non-resectable hepatic malignancies selective internal radiotherapy (SIRT) with yttrium-90 is an effective therapy. However, previous data indicate that SIRT leads to impaired immune function. The aim of the current study was to determine the extent of DNA lesions in peripheral blood mononuclear cells of SIRT patients and to correlate these lesions with cellular immune responses. In ten patients γH2AX and 53BP1 foci were determined. These foci are markers of DNA double-strand breaks (DSBs) and occur consecutively. In parallel, lymphocyte proliferation was assessed after stimulation with the T cell mitogen phytohemagglutinin. Analyses of vital cells were performed prior to and 1 h and 1 week after SIRT. 1 h and 1 week after SIRT numbers of γH2AX and of 53BP1 foci were more than threefold larger than before (p < 0.01). Already at baseline, foci were more abundant than published in healthy controls. Lymphocyte proliferation at baseline was below the normal range and further decreased after SIRT. Prior to therapy, there was an inverse correlation between lymphocyte proliferation and the quotient 53BP1/γH2AX; which could be considered as a measure of the course of DNA DSB repair (r = - 0.94, p < 0.0001). Proliferative responses were inversely correlated with 53BP1 foci prior to therapy and γH2AX and 53BP1 foci 1 h after therapy (r < - 0.65, p < 0.05). In conclusion, DNA foci in SIRT patients were correlated with impaired in vitro immune function. Unrepaired DNA DSBs or cell cycle arrest due to repair may cause this impairment.

Identifiants

pubmed: 30877323
doi: 10.1007/s00262-019-02323-x
pii: 10.1007/s00262-019-02323-x
doi:

Substances chimiques

H2AX protein, human 0
Histones 0
TP53BP1 protein, human 0
Tumor Suppressor p53-Binding Protein 1 0
Yttrium Radioisotopes 0
Yttrium-90 1K8M7UR6O1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

907-915

Auteurs

Aglaia Domouchtsidou (A)

Institute for Transfusion Medicine, University Hospital Essen, Virchowstraße 179, 45147, Essen, Germany.

Vahé Barsegian (V)

Institute of Nuclear Medicine, Helios Kliniken, Schwerin, Germany.

Stefan P Mueller (SP)

Department of Nuclear Medicine, University Hospital, Essen, Germany.

Pavel Lobachevsky (P)

Advanced Analytical Technologies, Melbourne, Australia.

Jan Best (J)

Department of Gastroenterology and Hepatology, University Hospital, Essen, Germany.
Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.

Peter A Horn (PA)

Institute for Transfusion Medicine, University Hospital Essen, Virchowstraße 179, 45147, Essen, Germany.

Andreas Bockisch (A)

Department of Nuclear Medicine, University Hospital, Essen, Germany.

Monika Lindemann (M)

Institute for Transfusion Medicine, University Hospital Essen, Virchowstraße 179, 45147, Essen, Germany. monika.lindemann@uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH